Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma: Individual Patient Data Meta-analysis

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Mirian, Christian ; Duun-Henriksen, Anne Katrine ; Maier, Andrea Daniela ; Pedersen, Maria Møller ; Jensen, Lasse Rehné ; Bashir, Asma ; Graillon, Thomas ; Hrachova, Maya ; Bota, Daniela ; van Essen, Martjin ; Spanjol, Petar ; Kreis, Christian ; Law, Ian ; Broholm, Helle ; Poulsgaard, Lars ; Fugleholm, Kåre ; Ziebell, Morten ; Munch, Tina ; Walter, Martin A ; Mathiesen, Tiit. / Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma : Individual Patient Data Meta-analysis. In: Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2021 ; Vol. 62, No. 4. pp. 507-513.

Bibtex

@article{ddd1df0d7b8f478ea27da42ea77c2aed,
title = "Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma: Individual Patient Data Meta-analysis",
abstract = "Somatostatin receptor (SSTR)-targeted peptide receptor radionuclide therapy (PRRT) represents a promising approach for treatment-refractory meningiomas. Methods: We performed an individual patient data meta-analysis, including all published data on meningioma patients treated with SSTR-targeted PRRT. The main outcomes were toxicity, response to treatment, progression-free survival (PFS), and overall survival (OS). We applied the Kaplan-Meier method to estimate survival probabilities and report incidence rates per 100 person-years. We applied Cox proportional hazards models to determine the effect of covariates. Results: We screened 537 papers and identified 6 eligible cohort studies. We included a total of 111 patients who had treatment-refractory meningioma and received SSTR-targeted PRRT. Disease control was achieved in 63% of patients. The 6-mo PFS rates were 94%, 48%, and 0% for World Health Organization grades I, II, and III, respectively. The risk of disease progression decreased by 13% per 1,000-MBq increase in the total applied activity. The 1-y OS rates were 88%, 71%, and 52% for World Health Organization grades I, II, and III, respectively. The risk of death decreased by 17% per 1,000-MBq increase in the total applied activity. The main side effects comprised transient hematotoxicity, such as anemia in 22% of patients, leukopenia in 13%, lymphocytopenia in 24%, and thrombocytopenia in 17%. Conclusion: To our knowledge, this individual patient data meta-analysis represents the most comprehensive analysis of the benefits of and adverse events associated with SSTR-targeted PRRT for treatment-refractory meningioma. The treatment was well tolerated, achieved disease control in most cases, and showed promising results regarding PFS and OS. ",
author = "Christian Mirian and Duun-Henriksen, {Anne Katrine} and Maier, {Andrea Daniela} and Pedersen, {Maria M{\o}ller} and Jensen, {Lasse Rehn{\'e}} and Asma Bashir and Thomas Graillon and Maya Hrachova and Daniela Bota and {van Essen}, Martjin and Petar Spanjol and Christian Kreis and Ian Law and Helle Broholm and Lars Poulsgaard and K{\aa}re Fugleholm and Morten Ziebell and Tina Munch and Walter, {Martin A} and Tiit Mathiesen",
note = "{\textcopyright} 2021 by the Society of Nuclear Medicine and Molecular Imaging.",
year = "2021",
month = apr,
doi = "10.2967/jnumed.120.249607",
language = "English",
volume = "62",
pages = "507--513",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine",
number = "4",

}

RIS

TY - JOUR

T1 - Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma

T2 - Individual Patient Data Meta-analysis

AU - Mirian, Christian

AU - Duun-Henriksen, Anne Katrine

AU - Maier, Andrea Daniela

AU - Pedersen, Maria Møller

AU - Jensen, Lasse Rehné

AU - Bashir, Asma

AU - Graillon, Thomas

AU - Hrachova, Maya

AU - Bota, Daniela

AU - van Essen, Martjin

AU - Spanjol, Petar

AU - Kreis, Christian

AU - Law, Ian

AU - Broholm, Helle

AU - Poulsgaard, Lars

AU - Fugleholm, Kåre

AU - Ziebell, Morten

AU - Munch, Tina

AU - Walter, Martin A

AU - Mathiesen, Tiit

N1 - © 2021 by the Society of Nuclear Medicine and Molecular Imaging.

PY - 2021/4

Y1 - 2021/4

N2 - Somatostatin receptor (SSTR)-targeted peptide receptor radionuclide therapy (PRRT) represents a promising approach for treatment-refractory meningiomas. Methods: We performed an individual patient data meta-analysis, including all published data on meningioma patients treated with SSTR-targeted PRRT. The main outcomes were toxicity, response to treatment, progression-free survival (PFS), and overall survival (OS). We applied the Kaplan-Meier method to estimate survival probabilities and report incidence rates per 100 person-years. We applied Cox proportional hazards models to determine the effect of covariates. Results: We screened 537 papers and identified 6 eligible cohort studies. We included a total of 111 patients who had treatment-refractory meningioma and received SSTR-targeted PRRT. Disease control was achieved in 63% of patients. The 6-mo PFS rates were 94%, 48%, and 0% for World Health Organization grades I, II, and III, respectively. The risk of disease progression decreased by 13% per 1,000-MBq increase in the total applied activity. The 1-y OS rates were 88%, 71%, and 52% for World Health Organization grades I, II, and III, respectively. The risk of death decreased by 17% per 1,000-MBq increase in the total applied activity. The main side effects comprised transient hematotoxicity, such as anemia in 22% of patients, leukopenia in 13%, lymphocytopenia in 24%, and thrombocytopenia in 17%. Conclusion: To our knowledge, this individual patient data meta-analysis represents the most comprehensive analysis of the benefits of and adverse events associated with SSTR-targeted PRRT for treatment-refractory meningioma. The treatment was well tolerated, achieved disease control in most cases, and showed promising results regarding PFS and OS.

AB - Somatostatin receptor (SSTR)-targeted peptide receptor radionuclide therapy (PRRT) represents a promising approach for treatment-refractory meningiomas. Methods: We performed an individual patient data meta-analysis, including all published data on meningioma patients treated with SSTR-targeted PRRT. The main outcomes were toxicity, response to treatment, progression-free survival (PFS), and overall survival (OS). We applied the Kaplan-Meier method to estimate survival probabilities and report incidence rates per 100 person-years. We applied Cox proportional hazards models to determine the effect of covariates. Results: We screened 537 papers and identified 6 eligible cohort studies. We included a total of 111 patients who had treatment-refractory meningioma and received SSTR-targeted PRRT. Disease control was achieved in 63% of patients. The 6-mo PFS rates were 94%, 48%, and 0% for World Health Organization grades I, II, and III, respectively. The risk of disease progression decreased by 13% per 1,000-MBq increase in the total applied activity. The 1-y OS rates were 88%, 71%, and 52% for World Health Organization grades I, II, and III, respectively. The risk of death decreased by 17% per 1,000-MBq increase in the total applied activity. The main side effects comprised transient hematotoxicity, such as anemia in 22% of patients, leukopenia in 13%, lymphocytopenia in 24%, and thrombocytopenia in 17%. Conclusion: To our knowledge, this individual patient data meta-analysis represents the most comprehensive analysis of the benefits of and adverse events associated with SSTR-targeted PRRT for treatment-refractory meningioma. The treatment was well tolerated, achieved disease control in most cases, and showed promising results regarding PFS and OS.

U2 - 10.2967/jnumed.120.249607

DO - 10.2967/jnumed.120.249607

M3 - Journal article

C2 - 32859705

VL - 62

SP - 507

EP - 513

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 4

ER -

ID: 61350973